Biology subjects

Mathews, E. W.

Publications and source records attributed to Mathews, E. W..

3 recordsLinked to original sources

bioRxiv2026

Hepatic huntingtin loss drives an acute phase response and liver injury in multiple mouse models

Multiple therapeutic strategies are being developed to slow Huntingtons disease (HD) progression through targeted reduction of huntingtin (HTT) protein or mRNA. Despite HTTs discovery over 30 years ago, its cellular functions remain incompletely understood, and the long-term consequences of HTT-lowering therapies remain unclear. We previously demonstrated that hepatic HTT loss in mice disrupts hepatocyte zonation and metabolism. Here, we investigate the physiological consequences of hepatic Htt loss. Across multiple models of Htt loss--including ubiquitous and hepatocyte-specific genetic knockouts and a therapeutically relevant Htt-targeting siRNA--there was elevated expression of IL-6/STAT3-driven acute phase response genes. Single-nucleus RNA sequencing reveals a zonal pattern of hepatocyte stress, most highly upregulated in pericentral hepatocytes, and identifies a distinct pericentral cluster of stressed hepatocytes that was enriched [~]9.6-fold following Htt knockout. Histological examination reveals that Htt loss results in increased hepatic pathology, including hepatic intranuclear inclusions, apoptosis, and necrosis, as well as prevalence of granulomas. Transcriptomic analysis reveals significant upregulation of metallothionein genes following Htt loss, as confirmed by elevated plasma metallothionein-1 (MT1) levels in knockout mice. These findings underscore important safety considerations for HTT-lowering therapies and suggest candidate biomarkers for monitoring hepatic off-target effects in clinical trials.

molecular biology↗

bioRxiv2024

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

Huntingtons disease (HD) arises from a CAG expansion in the huntingtin (HTT) gene beyond a critical threshold. A major thrust of current HD therapeutic development is lowering levels of mutant HTT mRNA (mHTT) and protein (mHTT) with the aim of reducing the toxicity of these product(s). Human genetic data also support a key role for somatic instability (SI) in HTTs CAG repeat - whereby it lengthens with age in specific somatic cell types - as a key driver of age of motor dysfunction onset. Thus, an attractive HD therapy would address both mHTT toxicity and SI, but to date the relationship between SI and HTT lowering remains unexplored. Here, we investigated multiple therapeutically-relevant HTT-lowering modalities to establish the relationship between HTT lowering and SI in HD knock-in mice. We find that repressing transcription of mutant Htt (mHtt) provides robust protection from SI, using diverse genetic and pharmacological approaches (antisense oligonucleotides, CRISPR-Cas9 genome editing, the Lac repressor, and virally delivered zinc finger transcriptional repressor proteins, ZFPs). However, we find that small interfering RNA (siRNA), a potent HTT-lowering treatment, lowers HTT levels without influencing SI and that SI is also normal in mice lacking 50% of total HTT levels, suggesting HTT levels, per se, do not modulate SI in trans. Remarkably, modified ZFPs that bind the mHtt locus, but lack a repressive domain, robustly protect from SI, despite not reducing HTT mRNA or protein levels. These results have important therapeutic implications in HD, as they suggest that DNA-targeted HTT-lowering treatments may have significant advantages compared to other HTT-lowering approaches, and that interaction of a DNA-binding protein and HTTs CAG repeats may provide protection from SI while sparing HTT expression.

neuroscience↗

bioRxiv2024

Global Huntingtin Knockout in Adult Mice Leads to Fatal Neurodegeneration that Spares the Pancreas

Huntingtons disease (HD) is a fatal neurogenerative disorder caused by an expanded glutamine-coding CAG tract in the Huntingtin (Htt) gene. HD is believed to primarily arise via a toxic gain of function, and as a result a wide range of Htt-lowering treatments are in clinical trials. The safety of these trials is contingent on the risks imposed by Htt lowering: Htt is widely conserved, ubiquitously expressed and its complete loss causes severe developmental symptoms in mice and humans. Recently, multiple labs have reported on the consequences of widespread inducible Htt loss in mice. One report describes that early induction of global Htt loss causes fatal pancreatitis, but that later onset lowering is benign. Another study did not report fatal pancreatitis but suggested that postnatal Htt loss was associated with widespread progressive phenotypes, including subcortical calcification and neurodegeneration. To better understand the risks posed by widespread inducible Htt loss we established the phenotypes of mice in which we knocked out Htt with two tamoxifen inducible Cre lines, which we have here extensively characterized. In short, we find that widespread loss of Htt at 2 months of age leads to a wide range of phenotypes, including subcortical calcification, but does not result in acute pancreatitis or histological changes in the pancreas. Additionally, we report here for the first time that Htt loss is followed by robust and sustained increases in the levels of neurofilament light chain (NfL), a peripherally accessible biomarker of neuroaxonal stress. These results confirm that complete loss of Htt in mice is associated with pronounced risks, including progressive subcortical calcification and neurodegeneration.

neuroscience↗